The 650,000 share increase to the equity plan provides headroom for future employee and director equity grants, but no immediate dilution event occurred. Monitor subsequent filings for actual option or RSU grants under the amended plan.
Price Chart
Executive Summary
CNS Pharmaceuticals held its 2026 Annual Meeting on September 30, 2026, where stockholders approved an amendment to the 2020 Equity Plan increasing authorized shares by 650,000 to a total of 765,061 shares. All six director nominees were elected, and the appointment of MaloneBailey, LLP as independent auditor was ratified. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved an amendment to the 2020 Equity Plan, increasing authorized shares by 650,000 to 765,061 total shares.
- All six director nominees (Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin, Amy Mahery) were elected.
- Ratification of MaloneBailey, LLP as independent registered public accounting firm for FY 2026 was approved (637,228 for, 30,874 against).
- Advisory vote on executive compensation passed (98,103 for, 6,682 against).
- Quorum was 45.72% (668,188 of 1,461,449 outstanding shares present or represented).
Financial Impact
No financial figures reported. The equity plan amendment authorizes up to 765,061 shares for future equity awards, but no grants were disclosed.
Risk Factors
- Potential future dilution from equity awards granted under the expanded plan.
- Low quorum (45.72%) indicates limited retail shareholder engagement.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007552 |
| Document: cns_8k.htm | 0001683168-26-007552 |
| Document: 0001683168-26-007552-index-headers.html | 0001683168-26-007552 |
| Document: 0001683168-26-007552-index.html | 0001683168-26-007552 |
| Document: 0001683168-26-007552.txt | 0001683168-26-007552 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $5.32 | awaiting T+20 | — | $5.08 (−4.60%) |
Jul 2, 2026 16w ago | 8-K | $5.07 $4.85 | ▼ −4.34% | ▼ −3.92% | $5.08 (+0.20%) |
May 27, 2026 21w ago | EFFECT | $5.12 $4.15 | ▲ +18.91% | ▲ +17.01% | $5.08 (+0.78%) |
May 19, 2026 23w ago | S-3 | $5.10 $4.70 | ▲ +7.84% | ▲ +8.58% | $5.08 (+0.39%) |
May 4, 2026 25w ago | 8-K | $7.84 $5.03 | ▲ +35.84% | ▲ +41.49% | $5.08 (+35.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers